PMID- 19292734
OWN - NLM
STAT- MEDLINE
DCOM- 20111223
LR  - 20211020
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 13
IP  - 9B
DP  - 2009 Sep
TI  - HER-2 overexpression/amplification in Barrett's oesophagus predicts early 
      transition from dysplasia to adenocarcinoma: a clinico-pathologic study.
PG  - 3826-33
LID - 10.1111/j.1582-4934.2008.00517.x [doi]
AB  - Barrett's oesophagus (BO) is the primary precursor lesion for oesophageal 
      adenocarcinoma (ADC). The natural history of metaplasia-dysplasia-carcinoma 
      sequence remains largely unknown. HER2/neu oncogene results 
      overexpressed/amplified in preneoplastic lesions and in ADC of the oesophagus and 
      it has been associated with poor prognosis. Our aim was to evaluate the role of 
      HER2 overexpression/amplification in predicting the conversion from precursor 
      lesions to ADC. We retrospectively evaluated by univariate analysis of single 
      variables clinical records and histological specimens of 21 patients with a 
      confirmed diagnosis of BO and/or oesophageal dysplasia. Clinical variables 
      included age, gender, alcohol and smoking intake, presence of symptoms (pyrosis, 
      disphagia) and endoscopic features (length). HER2 status was studied by 
      immunohistochemistry and fluorescence in situ hybridization (FISH) on 
      paraffin-embedded tissue. The end-points were the occurrence of progression and 
      the time-to-progression (TTP) from the initial histologic lesion to the worst 
      pathological pattern. Median age at diagnosis was 63 years (range 37-84). BO 
      median length was 4.5 cm. Progression occurred in 11 of 21 patients and median 
      TTP was 24 months. HER2 was overexpressed/amplified in 8 of 21 (38%) patients. 
      HER2 overexpression/ amplification and the presence of dysplasia were 
      statistically associated with progression (P= 0.038). This study provides 
      evidence for a possible role of HER2 in the transition from dysplasia to ADC of 
      the oesophagus. This fact could help in identifying patients at high risk of 
      malignant transformation.
FAU - Rossi, Elisa
AU  - Rossi E
AD  - 2nd Department of Pathology, Spedali Civili, Brescia, Italy.
FAU - Grisanti, Salvatore
AU  - Grisanti S
FAU - Villanacci, Vincenzo
AU  - Villanacci V
FAU - Della Casa, Domenico
AU  - Della Casa D
FAU - Cengia, Paolo
AU  - Cengia P
FAU - Missale, Guido
AU  - Missale G
FAU - Minelli, Luigi
AU  - Minelli L
FAU - Buglione, Michela
AU  - Buglione M
FAU - Cestari, Renzo
AU  - Cestari R
FAU - Bassotti, Gabrio
AU  - Bassotti G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081006
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Barrett Esophagus/*metabolism
MH  - Disease Progression
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*metabolism
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC4516530
EDAT- 2009/03/19 09:00
MHDA- 2011/12/24 06:00
PMCR- 2009/09/01
CRDT- 2009/03/19 09:00
PHST- 2009/03/19 09:00 [entrez]
PHST- 2009/03/19 09:00 [pubmed]
PHST- 2011/12/24 06:00 [medline]
PHST- 2009/09/01 00:00 [pmc-release]
AID - JCMM517 [pii]
AID - 10.1111/j.1582-4934.2008.00517.x [doi]
PST - ppublish
SO  - J Cell Mol Med. 2009 Sep;13(9B):3826-33. doi: 10.1111/j.1582-4934.2008.00517.x. 
      Epub 2008 Oct 6.